Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction

Circulation

Volumn 140, Issue 18, 2019, Pages

  Nassif, Michael E ^a,b   Windsor, Sheryl ^a   Tang, Fengming ^a   Khariton, Yevgeniy ^a,b   Husain, Mansoor ^c,d,e,f   Inzucchi, Silvio ^g   McGuire, Darren ^h   Pitt, Bertram ⁱ   Scirica, Benjamin ^j   Austin, Bethany ^a,b   Drazner, Mark ^h   Fong, Michael ^k   Givertz, Michael ^j   Gordon, Robert ^l   Jermyn, Rita ^m   Katz, Stuart ⁿ   Lamba, Sumant ^o   Lanfear, David ^p   LaRue, Shane ^q   Lindenfeld, JoAnn ^r   Malone, Michael ^s   Margulies, Kenneth ^t   Mentz, Robert ^u   Kannan Mutharasan, R ^v   Pursley, Michael ^w   Umpierrez, Guillermo ^x   Kosiborod, Mikhail ^a,b,y,z   Malik, Ali ^aa   Wenger, Nannette ^x   Ogunniyi, Modele ^x   Vellanki, Priyathama ^x   Murphy, Brenda ^ab   Newman, Jonathan ⁿ   Hartupee, Justin ^ac   Gupta, Charu ^ad   Goldsmith, Marcela ^ad   Baweja, Paramdeep ^ae   Montero, Manuel ^af   Gottlieb, Steve ^ag   Costanzo, Maria Rosa ^ah   Hoang, Thanh ^ai   Warnock, Alicia ^ai   Allen, Larry ^aj   Tang, Wilson ^ak   Chen, Horng ^al   Cox, John ^am   more..

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d TED ROGERS CENTRE FOR HEART RESEARCH   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^m St Francis Hospital   (United States)

ⁿ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^o First Coast Cardiovascular Institute   (United States)

^p HENRY FORD HOSPITAL   (United States)

^q WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r VANDERBILT UNIVERSITY   (United States)

^s Charlotte Heart Research Group   (United States)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u DUKE UNIVERSITY   (United States)

^v NORTHWESTERN UNIVERSITY   (United States)

^w Heart Group of the Eastern Shore   (United States)

^x EMORY UNIVERSITY   (United States)

^y GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^z UNIVERSITY OF NEW SOUTH WALES   (Australia)

^aa St Luke's Mid America Heart   (United States)

^ab First Coast Cardiovascular Institute

^ac Washington University   (United States)

^ad North Shore University   (United States)

^ae TRUMAN MEDICAL CENTER   (United States)

^af Nephrology Associates   (United States)

^ag UNIVERSITY OF MARYLAND   (United States)

^ah Health and Disability Advocates   (United States)

^ai WALTER REED ARMY MEDICAL CENTER   (United States)

^aj University of Colorado   (United States)

^ak LERNER RESEARCH INSTITUTE   (United States)

^al MAYO CLINIC   (United States)

^am Freeman Medical Center   (United States)

more..

Author keywords

Biomarkers; Health status; Heart failure; Outcomes; SGLT2 inhibitors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLUCOSE TRANSPORTER 2; HEMOGLOBIN A1C; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE;

ADULT; AGED; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PATHOPHYSIOLOGY;

AGED; BENZHYDRYL COMPOUNDS; BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 85073097480     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.042929     Document Type: Article

References (30)

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56-e528. doi: 10.1161/CIR.0000000000000659
2. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, et al; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606-619. doi: 10.1161/HHF.0b013e318291329a
3. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30-41. doi: 10.1038/nrcardio.2010.165
4. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077
5. Reddy P, Dunn AB. The effect of beta-blockers on health-related quality of life in patients with heart failure. Pharmacotherapy. 2000;20:679-689. doi:10.1592/phco.20.7.679.35178
6. Tsevat J, Weeks JC, Guadagnoli E, Tosteson AN, Mangione CM, Pliskin JS, Weinstein MC, Cleary PD. Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy. J Gen Intern Med. 1994;9:576-582. doi: 10.1007/bf02599287
7. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016-1024. doi: 10.1016/S1053-2498(01)00298-4
8. US FDA. Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. https://wwwfdagov/regulatory-information/searchfda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry. 2019.
9. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90-100. doi: 10.1177/1479164114559852
10. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi: 10.1056/NEJMoa1611925
11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720
12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357. doi: 10.1056/NEJMoa1812389
13. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. doi: 10.1056/NEJMoa1811744
14. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526-1534. doi: 10.1093/eurheartj/ehv728
15. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41:356-363. doi: 10.2337/dc17-1096
16. Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70:704-712. doi: 10.1016/j.jacc.2017.06.016
17. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, et al; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21:665-675. doi: 10.1002/ejhf.1432
18. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245-1255. doi: 10.1016/s0735-1097(00)00531-3
19. Nair DR, Mehta S, Mikhailidis DP. Assessing renal function - searching for the perfect marker continues! Arch Med Sci. 2011;7:565-567. doi: 10.5114/aoms.2011.24120
20. Araújo JP, Azevedo A, Lourenço P, Rocha-Gonçalves F, Ferreira A and Bettencourt P. Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol. 2006;98:1248-1250. doi: 10.1016/j.amjcard.2006.06.017
21. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J, Weintraub WS, et al; Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150:707-715. doi: 10.1016/j.ahj.2004.12.010
22. Schou M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail. 2007;9:68-74. doi: 10.1016/j.ejheart.2006.05.001
23. Schou M, Gustafsson F, Kjaer A, Hildebrandt PR. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J. 2007;28:177-182. doi:10.1093/eurheartj/ehl449
24. Miller WL, Hartman KA, Grill DE, Burnett JC, Jaffe AS. only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem. 2009;55:78-84. doi:10.1373/clinchem.2008.108928
25. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55:53-60. doi: 10.1016/j.jacc.2009.02.095
26. Dobre D, van Jaarsveld CH, deJongste MJ, Haaijer Ruskamp FM, Ranchor AV. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2007;16:152-159. doi: 10.1002/pds.1234
27. Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10:e003430. doi: 10.1161/ CIRCHEARTFAILURE.116.003430
28. Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395-2404. doi: 10.1093/ eurheartj/ehr343
29. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-2117. doi: 10.1007/s00125-018-4670-7
30. Flynn KE, Lin L, Moe GW, Howlett JG, Fine LJ, Spertus JA, McConnell TR, Piña IL, Weinfurt KP. Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. Am Heart J. 2012;163:88-94.e3. doi: 10.1016/j.ahj.2011.09.027